Vir Biotechnology, Inc. is planning to test its monoclonal antibody tobevibart, combined with the Alnylam Pharmaceuticals Inc.-partnered elebsiran, head-to-head against Gilead Sciences, Inc.’s Hepcludex (bulevirtide) in chronic hepatitis D, executives told analysts following the presentation of Phase II data for the combination at the European Association for the Study of the Liver (EASL) annual meeting.
Vir presented preliminary data on 5 June from the Phase II SOLSTICE study, showing a high virologic response and liver...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)